Find a clinical trial
Myeloproliferative Neoplasms (MPNs)
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential…
- Trial name
- CLARITY-101 (NCT07849231)
- Testing
- DMR-001, Ruxolitinib
- Where
- 36 sites in United States, Australia
- Volunteers
- 250 people
- Sponsor
- Damora Therapeutics
B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
Vasomotor Symptoms Associated With Menopause, Healthy Volunteers
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or…
- Trial name
- NCT07118891
- Testing
- ABCL635
- Where
- 13 sites in Canada
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AbCellera Biologics Inc.
Dravet Syndrome
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS.
- Trial name
- NCT06660394
- Testing
- LP352
- Where
- 105 sites in United States, Australia and 16 more
- Volunteers
- 108 people
- Sponsor
- Longboard Pharmaceuticals
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Advanced Ovarian Cancer
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian…
- Trial name
- Cornerstone4 (NCT05794659)
- Testing
- AST-201, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Aston Sci. Inc.
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
The trial aims to study the safety, tolerability, and pharmacokinetics of single and multiple rising doses of BI 3776528.
- Trial name
- NCT06745297
- Testing
- BI 3776528, short-acting benzodiazepine
- Where
- Germany
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hernia, Ventral, Hernia, Hiatal
GORE® ENFORM Biomaterial Product Study
A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair).
- Conditions
- Hernia, Ventral, Hernia, Hiatal, Hernia, Diaphragmatic, Incisional Hernia
- Trial name
- ENF 18-06 (NCT04718168)
- Testing
- Gore ENFORM Biomaterial (Preperitoneal), Gore ENFORM Biomaterial (Intraperitoneal)
- Where
- 9 sites in United States
- Volunteers
- 245 people
- Sponsor
- W.L.Gore & Associates
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme…
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
- Trial name
- NCT04686175
- Testing
- INZ-701
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 13 people
- Sponsor
- Inozyme Pharma
Fibrosing Interstitial Lung Disease
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary…
- Trial name
- NCT07366034
- Testing
- Nerandomilast
- Where
- 47 sites in United States, Argentina and 20 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- emnergize (NCT07091630)
- Testing
- Empasiprubart IV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 160 people
- Sponsor
- argenx
Non-alcoholic Fatty Liver Disease
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated.
- Trial name
- SKYLINE (NCT06104319)
- Testing
- GSK4532990
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Urinary Incontinence
Augmenting Urinary Reflex Activity: Study 3
AURA-3 study (Augmenting Urinary Reflex Activity Study 3) is a single arm, short-duration (8 month) cohort follow up study of preceding interventional medical device study, AURA-2.
- Trial name
- AURA-3 (NCT06597994)
- Testing
- Amber UI system
- Where
- Belgium
- Volunteers
- 11 people
- Sponsor
- Amber Therapeutics Ltd
Polyneuropathy, Inflammatory Demyelinating, Chronic
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating…
- Trial name
- LTS (NCT06859099)
- Testing
- Riliprubart Prefilled Pen (PFP)
- Where
- 63 sites in United States, Argentina and 22 more
- Volunteers
- 300 people
- Sponsor
- Sanofi
Androgenic Alopecia, Hair Loss/Baldness
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss).
- Conditions
- Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
- Trial name
- NCT07637071
- Testing
- Xtressé Hair Growth Gummies
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Renal Cell Carcinoma
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced…
- Trial name
- NCT05468697
- Testing
- Belzutifan, Palbociclib
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis D
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
- Trial name
- NCT07454837
- Testing
- Brelovitug (BJT-778), Bulevirtide
- Where
- 46 sites in Austria, Czechia and 6 more
- Volunteers
- 120 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Ulcerative Colitis, Inflammatory Bowel Diseases
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Trial name
- SKYLINE-UC (NCT07012395)
- Testing
- SPY001, SPY002, SPY003
- Where
- 276 sites in United States, Argentina and 33 more
- Volunteers
- 645 people
- Sponsor
- Spyre Therapeutics, Inc.
Niemann-Pick Type C Disease, GM1 Gangliosidosis
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in…
- Conditions
- Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
- Trial name
- NCT07054515
- Testing
- AZ-3102
- Where
- 39 sites in United States, Argentina and 15 more
- Volunteers
- 147 people
- Sponsor
- Azafaros B.V.
Hemophilia
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to <12 years) who have severe hemophilia A or…
- Trial name
- ATLAS-KIDS (NCT07285460)
- Testing
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 37 sites in United States, Belgium and 10 more
- Volunteers
- 85 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.